All In Biotech

Drug Trial Radar · NCT00535574

Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia

Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia: a 6-week, Randomized, Double-blind Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: Jul 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

90

Actual

Start

Nov 2008

Primary completion

Dec 2010

Study completion May 2011

Sponsor

Lead sponsor
Beersheva Mental Health CenterGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Sep 26, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: Bexarotene (Targretin) is a synthetic retinoid mainly used for treatment of patients suffer from oncological or dermatological diseases. The present study is based on: evidence that retinoids are involved in neurodevelopment ("the retinoid dysregulation hypothesis"); an assumption that the combined effect of antipsychotic agents and bexarotene will have a beneficial effect on schizophrenia patients; and the positive findings from our pilot open-label clinical trial (ClinicalTrials.gov Identifier: NCT00141947). However, clinical efficacy of bexarotene should be investigated in a placebo-controlled trial. Methods: In a 6-week, randomized, double-blind placebo-controlled trial Targretin (75 mg/day) or placebo capsules will be added to the stable ongoing antipsychotic treatment of 90 schizophrenia patients. Participants will be assessed at baseline and after 2, 4 and 6 weeks of treatment. A battery of research instruments will be used for assessment of psychopathology, side effects, general functioning and quality of life. In addition, cholesterol and triglyceride levels, liver and thyroid function tests and a blood cell count will be monitored at baseline and during the study

Conditions

  • Schizophrenia

Interventions

  • Bexarotene (Targretin LGD1069)Drug

    75 mg per day for 6 weeks

  • bexaroteneDrug

    75 mg/day 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PANSS, CDSS, GAF, QLSTime frame: every two weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Abarbanel Mental Health Center

    Bat Yam, Israel

  • Sha'ar Menashe Mental Health Center,

    Hadera, Israel

  • Be'er Sheva Mental Health Center

    Beersheba, Be'er Sheva, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.